Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
The Genetic Blueprint Behind PAH – Clinical Correlates and Prognostic Implications
Session:
Sessão de Posters 57 - Hipertensão arterial pulmonar: estratificação de risco, hemodinâmica e prognóstico
Speaker:
Nuno Alexandre Dias Madruga
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
Subtheme:
21.2 Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Nuno Madruga; Daniel Inácio Cazeiro; Diogo Ferreira; João Cravo; Marta Vilela; Maria João Oliveira; Ana Rocha Dias; Oana Moldovan; Tatiana Guimarães; Nuno Lousada; Fausto J. Pinto; Rui Plácido
Abstract
<p><strong>Introduction: </strong>Genetic predisposition plays a key role in the pathobiology of pulmonary arterial hypertension (PAH). With the expanding availability of next-generation sequencing (NGS), clinicians can now detect a broad spectrum of pathogenic and emerging variants across PAH-associated genes. However, the true clinical consequences of these findings – particularly their impact on phenotype and prognosis – remain undefined.</p> <p> </p> <p><strong>Aim: </strong>To characterize the genetic landscape of a contemporary PAH cohort and compare clinical features and outcomes between patients (pts) with and without identified genetic variants.</p> <p> </p> <p><strong>Methods: </strong>Retrospective, single-center study of pts with PAH who underwent genetic testing (GT) from 2012 to 2025. Testing consisted of BMPR2 sequencing or multigene NGS panels. Baseline patient characteristics were collected at diagnosis. Pts with a positive GT (GT+) were compared to those without identified variants (GT–). Group comparisons were performed with t-tests or Mann–Whitney tests, as appropriate. Time to all-cause death/hospitalization was assessed with Kaplan–Meier and log-rank analysis.</p> <p> </p> <p><strong>Results: </strong>Of 78 GT performed, 63 generated reportable results. A total of 24 variants were identified across multiple PAH-associated genes – BMPR2 (50%), ACVRL1 (13%), EIF2AK4 (13%), ABCC8 (4%), FOXF1 (4%), SMAD9 (4%), KDR (4%), ENG (4%), and GDF2 (4%). The overall diagnostic yield was 38%; pathogenic (P) / likely pathogenic (LP) variants were detected in 14 pts (22% yield).</p> <p>Compared with GT– pts (n=36), GT+ pts (n=21) were younger at diagnosis (42 vs. 51 years, p=0.027). Baseline WHO functional class, NTproBNP and 6-minute walk distance were similar between groups. Echocardiographic parameters were comparable except for a significantly lower TAPSE/sPAP ratio in GT+ pts (0.24±0.14 vs. 0.40±0.15 mm/mmHg, p=0.018). Hemodynamically, GT+ pts had numerically higher pulmonary vascular resistance (14.1 vs. 10.6 WU, p=NS) and significantly lower cardiac index (1.86 vs. 2.56 L/min/m², p=0.004). </p> <p>During a mean follow-up of 4.2 years, no differences were observed between GT+ and GT– pts in all-cause mortality (p=0.777) or in the composite outcome of death or hospitalization (p=0.654). Stratification by type of variant (P/LP vs. VUS/negative) likewise revealed no differences in event-free survival. </p> <p> </p> <p><strong>Conclusion: </strong>GT demonstrated a robust diagnostic yield and identified variants across a wide range of PAH-associated genes. GT+ pts were younger and exhibited a more adverse hemodynamic profile – particularly regarding right ventricular–pulmonary arterial coupling. Despite these differences, genetic status did not translate into measurable differences in long-term clinical outcomes. These findings underscore the complexity of genetic influences in PAH and emphasize the need for larger cohorts to clarify how specific variants interact with phenotype, treatment response and prognosis.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site